ATLANTA, GA – – (Globe Newswire – December 10, 2024) – – A shareholder class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX). The lawsuit alleges that the Company’s Offering Documents issued in connection with its IPO were negligently prepared because Defendants failed to disclose adverse data it possessed in regards to one of its clinical trials.

If you bought shares of Kyverna on or after February 8, 2024 and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/kyverna-therapeutics/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is February 7, 2025.